Last reviewed · How we verify

Boostrix TM — Competitive Intelligence Brief

Boostrix TM (Boostrix TM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine (toxoid and acellular pertussis). Area: Immunology / Infectious Disease.

marketed Combination vaccine (toxoid and acellular pertussis) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Boostrix TM (Boostrix TM) — GlaxoSmithKline. Boostrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Boostrix TM TARGET Boostrix TM GlaxoSmithKline marketed Combination vaccine (toxoid and acellular pertussis)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine (toxoid and acellular pertussis) class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Boostrix TM — Competitive Intelligence Brief. https://druglandscape.com/ci/boostrix-tm. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: